Results 61 to 70 of about 25,222 (249)

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide

Harm Reduction Journal, 2012
Background Respiratory depression, a potentially fatal side-effect of opioid-overdose, may be reversed by timely administration of an opioid antagonist, such as naloxone or naltrexone.
Goli Veeraindar, Webster Lynn R, Lamson Michael J, Cleveland Jody M, Sommerville Kenneth W, Carter Eric   +5 more
doaj   +1 more source

Comparison of Disulfiram and Naltrexone in Cases of Alcohol Dependence Syndrome

Journal of Nepal Health Research Council, 2020
Background: Relapse prevention in alcoholism is recognised as an important component of management. Use of pharmacotherapies to prevent relapse in combination to psychological intervention is emerging.
Sandarba Adhikari, Pratikchya Tulachan, Saroj Prasad Ojha, Manisha Chapagai, Saraswati Dhungana, Sagun Ballav Pant   +5 more
doaj   +1 more source

Stress-evoked opioid release inhibits pain in major depressive disorder [PDF]

, 2008
To determine whether stress-evoked release of endogenous opioids might account for hypoalgesia in major depressive disorder (MDD), the μ-opioid antagonist naltrexone (50 mg) or placebo was administered double-blind to 24 participants with MDD and to 31 ...
Frew, A.K., Drummond, P.D.
core  

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum with high-performance liquid chromatography

BMC Research Notes, 2012
Background Naltrexone has been proven to be an effective treatment option for the treatment of alcohol dependency. In this article we introduce a reliable and simple method developed for the simultaneous determination of naltrexone and 6-β-naltrexol in ...
Heinälä Pekka, Lahti Tuuli, Sinclair David, Ariniemi Kari, Lillsunde Pirjo, Alho Hannu   +5 more
doaj   +1 more source

A Narrative Review on Bio-Physiology of Naltrexone Treatment in Pornography Addiction

Problematic pornography use remains a debatable entity, with features overlapping behavioral addictions and impulse control disorders. The controversial nosological status also provides challenges in formulating management plans as there exists no proven
Manoj Kumar Sharma, H. Ravish, Sidharth Arya   +2 more
core   +1 more source

Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson, Thomas Parkhouse, Chloe Burke, Monika Halicka, Jennifer C. Palmer, Hend Gabr, Rebecca Wilson, Katie E. Webster, Francesca Spiga, Sarah Dawson, Deborah M. Caldwell, Jennifer Scott, Julian P. T. Higgins, Jelena Savović   +13 more
wiley   +1 more source

Is alcohol craving reduced in patients prescribed naltrexone who also carry the OPRM1 Asn40Asp polymorphism (RS1799971)?

, 2021
Purpose: The precise mechanisms that naltrexone acts on the brain to improve alcohol dependence treatment outcomes is unknown. Naltrexone is a Mu- opioid antagonist that blocks endogenous opioid reward and is thought to reduce alcohol cue-conditioned ...
Connor, JP, Law, B, Gullo, MJ, Clark, P, Feeney, GFX, Coates, JM, Young, R McD, Voisey, J   +7 more
core   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source